ストックスクリーナーアプリを入手
2.55
6.69%
0.16
プレマーケット:
2.52
-0.03
-1.18%
Organogenesis Holdings Inc (ORGO) 最新ニュース
Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organogenesis reports positive trial results for wound care product - Investing.com
Organogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg Ulcers - Quiver Quantitative
Peer-reviewed Affinity trial finds higher closure in leg wounds over 24 months - Stock Titan
ORGO|Organogenesis Holdings Inc|Price:2.390|Chg%:-0.040 - TradingKey
Organogenesis Holdings Inc (ORGO) Cash Flow - TradingKey
ORGO|Organogenesis Holdings Inc|Price:2.550|Chg%:+0.160 - TradingKey
Organogenesis Holdings Inc (ORGO) Balance Sheet - TradingKey
Organogenesis Holdings Inc (ORGO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organogenesis Holdings Inc - TradingKey
Organogenesis Holdings Inc (ORGO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organogenesis Holdings Inc (ORGO) Institutional Confidence - TradingKey
TradingKey - TradingKey
Organogenesis Holdings, Inc. Class A Revenue Breakdown – DUS:2PQ - TradingView
Organogenesis Holdings Inc. (ORGO) stock price, news, quote and history - Yahoo Finance Singapore
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORGO INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Organogenesis Holdings (ORGO) Investors with Substantial Losses to Contact Firm's Attorneys, Securities Fraud Class Action Filed - TMX Newsfile
Organogenesis Holdings Inc (ORGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ORGO|Organogenesis Holdings Inc|Price:2.335|Chg%:-0.095 - TradingKey
Organogenesis Holdings (ORGO) Slides 7.8% as Stock Tests Key Support ZoneIV Expansion Alert - dars.gov.et
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
3 Penny Stocks With Market Caps Over $100M To Consider - simplywall.st
Organogenesis Holdings (ORGO) Slips 1.87% as Resistance Holds; Key Levels in FocusSell Signal Alerts - dars.gov.et
Organogenesis stock trades steadily as wound care margins support outlook - Ad-hoc-news.de
Organogenesis Holdings (ORGO) Surges 7.23% as Stock Finds Traction Above SupportOvernight Profile - dars.gov.et
ORGO Q1 2026 Earnings: EPS Miss by Significant Margin, Stock DeclinesQuarterly Profit Report - dars.gov.et
Organogenesis (ORGO) AGM 2026 Summary - Quartr
Organogenesis (ORGO) Proxy filing Summary - Quartr
Organogenesis (ORGO) Q1 2026 earnings summary - Quartr
Organogenesis (ORGO) Q1 2025 earnings summary - Quartr
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 - The Manila Times
Organogenesis Holdings (ORGO) Q1 2026 Earnings: Substantial EPS Miss Pressures SharesEarnings Acceleration Picks - dars.gov.et
Organogenesis Holdings outlines regenerative medicine path as investors weigh long-term growth - ad-hoc-news.de
Organogenesis Amnuvx Gets FDA Review for Knee OA - AllSci
FDA accepts Organogenesis’ application for knee osteoarthritis treatment - Investing.com
FDA accepts Organogenesis’ application for knee osteoarthritis treatment By Investing.com - Investing.com Nigeria
Organogenesis' Biologics License Application for ReNu Accepted by FDA for Review - Moomoo
FDA accepts Organogenesis' Biologics License Ap... - Pluang
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis - The Manila Times
Organogenesis wins FDA review for ReNu, a knee osteoarthritis treatment - Stock Titan
ORGO Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesCFO Commentary Report - dars.gov.et
ORGO Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesUpward Estimate Revision - dars.gov.et
Enterprise value to revenue forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to book forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to sales forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis | 10-K: FY2025 Annual Report - Moomoo
Enterprise value to EBITDA forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to earnings forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Price to earnings forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM: ORGO) added to Russell 2000 Value Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell 3000E Value Benchmark - marketscreener.com
Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO) - TradingView
ORGO Forecast — Price Target — Prediction for 2027 - TradingView
Organogenesis Holdings Inc (ORGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Organogenesis Holdings (ORGO) Edges Higher as Shares Approach Key ResistanceVolume Breadth - dars.gov.et
0.30%
2.01%
大文字化:
|
ボリューム (24 時間):